Bristol-Myers Squibb Co  

(Public, OTCMKTS:BMYMP)   Watch this stock  
Find more results for NYSE:BMY-
+182.36 (20.33%)
Apr 23 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 891.73 - 1,079.17
52 week 829.79 - 1,079.17
Open 891.73
Vol / Avg. 54.00/5.00
Mkt cap 101.67B
P/E 697.48
Div/yield 0.36/0.13
EPS 1.55
Shares 94.21M
Beta 0.36
Inst. own 1247%
Jun 2, 2014
Bristol-Myers Squibb Investor Event: ASCO 2014 - Tentative - 8:00AM EDT - Add to calendar
May 6, 2014
Bristol-Myers Squibb Annual Shareholder Meeting - 10:00AM EDT - Add to calendar
Apr 29, 2014
Q1 2014 Bristol-Myers Squibb Earnings Release - 9:30AM EDT - Add to calendar
Apr 29, 2014
Q1 2014 Bristol-Myers Squibb Earnings Conference Call - 9:00AM EDT - Add to calendar
Mar 29, 2014
Bristol-Myers Squibb at American College of Cardiology (ACC) 2014: 63rd Annual Scientific Session & Expo
Mar 4, 2014
Bristol-Myers Squibb at Cowen Health Care Conference
Mar 4, 2014
Bristol-Myers Squibb at Credit Suisse Healthcare Conference
Feb 24, 2014
Bristol-Myers Squibb at Citi Global Healthcare Conference
Feb 12, 2014
Bristol-Myers Squibb at Leerink Swann Global Healthcare Conference - Webcast
Jan 24, 2014
Q4 2013 Bristol-Myers Squibb Earnings Conference Call

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 16.55% 15.75%
Operating margin 19.25% 17.20%
EBITD margin - 24.36%
Return on average assets 7.82% 6.93%
Return on average equity 19.49% 17.81%
Employees 28,000 -
CDP Score - 96 B


NEW YORK, NY 10154
United States - Map
+1-212-5464000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

About Company - Wikipedia


Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in 6 foreign countries. In February 2012, it acquired Inhibitex, Inc. (Inhibitex). In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. In August 2012, Synergy Pharmaceuticals Inc announced that it signed an Asset Purchase Agreement with the Company and acquired the assets related to FV-100, an orally available nucleoside analogue, being developed for the treatment of shingles. In February 2014, Bristol-Myers Squibb Co completed the sale of its global diabetes business to AstraZeneca.

Officers and directors

Lamberto Andreotti Chief Executive Officer, Director
Age: 63
Trading Activity - Yahoo Finance
Charles A. Bancroft Chief Financial Officer, Executive Vice President
Age: 54
Louis S. Schmukler President - Global Manufacturing and Supply
Age: 58
Francis M. Cuss Executive Vice President, Chief Scientific Officer
Age: 59
Giovanni Caforio M.D. Executive Vice President, Chief Commercial Officer
Age: 49
Paul von Autenried Senior Vice President - Enterprise Services, Chief Information Officer
Age: 52
Anne Nielsen Senior Vice President, Chief Compliance and Ethics Officer
Age: 53
Joseph C. Caldarella Senior Vice President, Corporate Controller
Age: 58
Trading Activity - Yahoo Finance
Ann Powell Judge Senior Vice President - Global Human Resources
Age: 47
John E. Elicker Senior Vice President - Public Affairs and Investor Relations
Age: 54